Cancer Patients May Be Treated With Drugs That Provide No Benefit
Many cancer patients may be treated with drugs that were granted accelerated approval but do not provide a clinical benefit, a study suggests.
Many cancer patients may be treated with drugs that were granted accelerated approval but do not provide a clinical benefit, a study suggests.
Aggregated data can hide disparities in cancer incidence and outcomes among Asian and Native Hawaiian/Pacific Islander patients in the US.
The IMbrave050 study included 662 patients with HCC at high risk for recurrence after surgical resection or ablation with curative intent.
Cell-free DNA fragmentome analysis can be used to detect hepatocellular carcinoma, according to researchers.
Researchers sought to determine the relationship between direct radiation dose and inflammation and regional hepatic function after stereotactic body radiation therapy for hepatocellular carcinoma.
Researchers found that hepatocellular carcinoma surveillance was underutilized among approximately 80% of patients with cirrhosis.
The effect of compliance with ERAS protocols on postoperative adverse events and length of hospital stay was evaluated in a single-center cohort study.
The combination of sintilimab and IBI305 improved progression-free survival in patients with unresectable hepatocellular carcinoma.
Overall survival was superior with donafenib.
Patient reported outcomes for quality of life, emotional and social functioning, and general disease symptoms were better with atezolizumab/bevacizumab compared with sorafenib monotherapy.